The U.S. Food and Drug Administration has approved Axsome Therapeutics' Symbravo (meloxicam and rizatriptan) for the acute ...

CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.CTQLEHs_.js ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Cyclarity Therapeutics of Novato has clearance to proceed with a clinical human trial in the fight against acute coronary syndrome.

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in the ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

In the Phase II MAIA lung cancer trial, THIO improved patients’ overall survival when taken in combination with Libtayo.